Loading company details…
Pletalion Therapeutics develops novel targeted dendrimer‑conjugate therapies for cancer patients.
| Allotment | Filed | Share Class | Round Size | Round Type |
|---|---|---|---|---|
2024-04-08 | £403.3M |
| Shareholder | Share class | Shares | Holding |
|---|---|---|---|
| MEDICXI IV LPCORP | SERIES A | 5,899,600 | 69.1% |
| 8888888888888888888888 | 8888888888 | 8888888 | 88888 |
| 88888888888888888888888888 | 8888888888 | 8888888 | 88888 |
| 888888888888888888 | 8888888888 | 888888 | 8888 |
| 8888888888888 | 88888888 | 888888 |
Companies with the most similar business descriptions.
These are the directors and secretaries who have left PETALION THERAPEUTICS LIMITED. A resignation is filed with Companies House on form TM01 and the date below is the date the officer's appointment ended, not the date it was filed. Departures matter for reading a company's history: a founder leaving shortly after a funding round, or several directors resigning at once, is often the visible trace of a change of control or a restructure.
| 8888888888888 | 88888888 | 888888 | 8888 |
6 more shareholders on file , sign up free to see.